All AbMole products are for research use only, cannot be used for human consumption.
In vitro: The estimated EC50 for total 8 concentration in plasma is 3.8 μM, which corresponds well with the IC50 value obtained in the human whole blood assay of 1.9 μM.
In vivo: PF-06282999 is moderately bound to plasma proteins across preclinical species and humans. The blood/plasma ratios for PF-06282999 are 1.1, 1.1, 0.91, 1.2, and 0.94 in mice, rats, dogs, monkeys, and humans, respectively, suggesting that PF-06282999 is equally distributed into plasma and red blood cells. The in vivo pharmacokinetics of PF-06282999 are examined in greater detail in mice, rats, dogs, and monkeys, wherein it is demonstrated to have low CLp in mice (10.1 mL/min/kg), dogs (3.39 mL/min/kg), monkeys (10.3 mL/min/kg) and moderate CLp in rats (41.8 mL/min/kg). The terminal plasma elimination half-lives (t1/2) range from 0.75 to 3.3 h in the four species. Approximately 26-32% of the iv dose of PF-06282999 is excreted in the unchanged form in rat, dog, and monkey urine, wherein it is also shown that it is well distributed with steady state distribution volumes (Vdss) ranging from 0.5-2.1 L/kg in mice, rats, dogs, and monkeys. Following oral administration, PF-06282999 is rapidly (Tmax=0.78-1.70 h) and well absorbed in mice, rats, dogs, and monkeys with oral bioavailability values of 100%, 86%, 75%, and 76%, respectively.
| Cell Experiment | |
|---|---|
| Cell lines | HepaRG KO Cell Lines |
| Preparation method | Following the pre-incubation period, cells were treated with 200 μl/well of the prepared 1x-concentration treatment medium with control DMSO (0.1%), PF 06282999 (1-600 μM) or rifampin (0.03-30 μM). |
| Concentrations | 1-600 μM |
| Incubation time | 48 h |
| Animal Experiment | |
|---|---|
| Animal models | |
| Formulation | |
| Dosages | |
| Administration | |
| Molecular Weight | 325.77 |
| Formula | C13H12ClN3O3S |
| CAS Number | 1435467-37-0 |
| Form | Solid |
| Solubility (25°C) | 32 mg/mL in DMSO |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related Products |
|---|
| GAPDH-IN-1
GAPDH-IN-1 (GAPDH Inhibitor Compound F8) is a covalent inhibitor of GAPDH (IC50 = 39.31 µM). It viability of, and glucose metabolism in, HEK293 cells in a concentration-dependent manner. |
| O-acetylcamptothecin
O-acetylcamptothecin is a derivative of camptothecin, a naturally occurring alkaloid extracted from the bark of the Chinese tree Camptotheca acuminata. Camptothecin and its derivatives are primarily known for their potent anticancer properties, particularly through their action as inhibitors of topoisomerase I, an enzyme critical for DNA replication and transcription. |
| 10-hydroxystearic acid
10-hydroxystearic acid is a hydroxy fatty acid. |
| SB-T-1214
SB-T-1214 is a new-generation taxoid. SB-T-1214 possesses significant activity against colon cancer spheroids induced by and enriched with drug resistant tumorigenic CD133high/CD44high cells and efficiently inhibited expression of the majority of stem cell-related genes. |
| NG-497
NG-497 is a selective human adipose triglyceride lipase (ATGL) inhibitor that targets the enzymatically active patatin-like domain of human ATGL. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
